
Good morning.
Moderna is repositioning itself in the biotechnology space by betting on new innovation based on its mRNA platform. Moderna CFO Jamey Mock will play a major role in mitigating risk in these big investments as demand for the company’s only marketable product at this time—the COVID-19 vaccine—lags.